Theralase Launches New Head Office and Therapeutic Laser Centre

479 views
413 views

Published on

Theralase Technologies Inc. designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neuro musculoskeletal conditions and wound healing. Theralase is currently developing proprietary Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
479
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Theralase Launches New Head Office and Therapeutic Laser Centre

  1. 1. Press ReleaseTheralase Launches New Head Office and Therapeutic Laser CentreToronto, ON – May 28, 2013 - Theralase Technologies Inc. (TSX-V: TLT), announced today the launch ofits new head office and multidisciplinary therapeutic laser centre in the heart of the Beach District ofToronto, Ontario. The new laser centre will provide local patients with a proven, highly effective, non-invasive treatment to address painful and inflamed medical conditions, without the need for surgery orpharmaceutical drugs, and their associated side effects.“The Centre will be a multidisciplinary pain and rehabilitation treatment centre focused on deliveringTheralase therapeutic laser therapy treatments through mainstream medical practitioners, such as:medical doctors, chiropractors, physical therapists, naturopathic doctors, doctors of podiatry andregistered massage therapists,” said Dr. Rhonda Mostyn, Clinic Director of Theralase Therapeutic LaserCentre. “Our initial focus will be primarily chronic and acute pain caused by neural muscular skeletalconditions, sports injuries, motor vehicle accidents or trauma, but as the centre grows, we may branchout into other disciplines such as wound healing and addiction.”“With regards to our growing number of customers, the new training facility will provide state of theart conferencing technology and training sessions on our cutting-edge technology, laser therapycertification courses and the latest treatment protocol optimization support,” said Roger DumoulinWhite, President and CEO of Theralase Technologies. “The new corporate head office, in addition tohousing executive management, finance, sales and marketing functions will also support an ISO-13485certified, Health Canada, FDA and CE approved facility to manufacture the Theralase line of therapeuticlasers, as well as aftermarket sales and service support for all of Theralase’s healthcare customers.Thousands of satisfied healthcare practitioners and patients throughout North America attest to thesafety and effectiveness of Theralase’s laser technology. We expect the laser centre to be verysuccessful in the near term adding a significant revenue stream to the Company.”The corporate head office and therapeutic laser centre will now be located at, 1945 Queen Street East,Toronto, Ontario, Canada, M4L 1H7, Phone: 416-699-LASE (5273), Toll-free: 1-866-843-LASE (5273),Fax: 416-699-5250, and will be open from 7:00 am to 7:00 pm 7 days a week to fully service our localpatients and our international sales team.About Theralase Technologies Inc.:Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralasetechnology is safe and effective in treating pain, inflammation and for tissue regeneration of neuromusculoskeletal conditions and wound healing. Theralase is currently developing proprietary PhotoDynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses whenlight activated by Theralase’s proprietary and patented laser technology.For further information please visit www.theralase.com , regulatory filings may be viewed by visitingwww.sedar.com.
  2. 2. Press ReleaseThis press release contains forward-looking statements, which reflect the Companys current expectations regarding future events. The forward-lookingstatements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation toupdate these forward-looking statements.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) acceptsresponsibility for the adequacy or accuracy of this release.For More Information:Roger Dumoulin-WhitePresident & CEO416-699-LASE (5273) ext. 225rwhite@theralase.comKristina HacheyChief Financial Officer416-699-LASE (5273) ext. 224khachey@theralase.comArkady MandelChief Scientific Officer416-699-LASE (5273) ext. 242amandel@theralase.comGreg BewshDirector of Investor Relations416-699-LASE (5273) ext. 258gbewsh@theralase.com

×